Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.38
CBST's Cash to Debt is ranked higher than
54% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.07 vs. CBST: 0.38 )
CBST' s 10-Year Cash to Debt Range
Min: 0.19   Max: 35.27
Current: 0.38

0.19
35.27
Equity to Asset 0.47
CBST's Equity to Asset is ranked higher than
61% of the 772 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CBST: 0.47 )
CBST' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.95
Current: 0.47

-0.48
0.95
Interest Coverage 0.70
CBST's Interest Coverage is ranked lower than
52% of the 447 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBST: 0.70 )
CBST' s 10-Year Interest Coverage Range
Min: 0.31   Max: 7.41
Current: 0.7

0.31
7.41
F-Score: 3
Z-Score: 2.01
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 10.54
CBST's Operating margin (%) is ranked higher than
88% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -55.17 vs. CBST: 10.54 )
CBST' s 10-Year Operating margin (%) Range
Min: -2763   Max: 29.79
Current: 10.54

-2763
29.79
Net-margin (%) 5.59
CBST's Net-margin (%) is ranked higher than
85% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: -51.98 vs. CBST: 5.59 )
CBST' s 10-Year Net-margin (%) Range
Min: -3094.81   Max: 29.49
Current: 5.59

-3094.81
29.49
ROE (%) 4.49
CBST's ROE (%) is ranked higher than
85% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -25.77 vs. CBST: 4.49 )
CBST' s 10-Year ROE (%) Range
Min: -5818.4   Max: 69.13
Current: 4.49

-5818.4
69.13
ROA (%) 2.10
CBST's ROA (%) is ranked higher than
85% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -19.98 vs. CBST: 2.10 )
CBST' s 10-Year ROA (%) Range
Min: -73.44   Max: 20.9
Current: 2.1

-73.44
20.9
ROC (Joel Greenblatt) (%) 34.14
CBST's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -210.62 vs. CBST: 34.14 )
CBST' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -300.09   Max: 141.6
Current: 34.14

-300.09
141.6
Revenue Growth (%) 15.00
CBST's Revenue Growth (%) is ranked higher than
87% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. CBST: 15.00 )
CBST' s 10-Year Revenue Growth (%) Range
Min: -41.3   Max: 209.9
Current: 15

-41.3
209.9
EBITDA Growth (%) -43.60
CBST's EBITDA Growth (%) is ranked higher than
57% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CBST: -43.60 )
CBST' s 10-Year EBITDA Growth (%) Range
Min: -46.9   Max: 93.6
Current: -43.6

-46.9
93.6
» CBST's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CBST Guru Trades in Q3 2013

Andreas Halvorsen 594,704 sh (New)
John Burbank 202,451 sh (New)
Pioneer Investments 686,436 sh (+357.01%)
Chuck Royce 425,800 sh (+29.74%)
RS Investment Management 622,011 sh (+25.03%)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Murray Stahl 24,000 sh (unchged)
Stanley Druckenmiller 413,000 sh (unchged)
Joel Greenblatt 25,996 sh (unchged)
Michael Price Sold Out
George Soros 150,000 sh (-14.29%)
Jim Simons 324,620 sh (-29.77%)
Steven Cohen 60,503 sh (-33%)
» More
Q4 2013

CBST Guru Trades in Q4 2013

Paul Tudor Jones 3,348 sh (New)
Andreas Halvorsen 741,700 sh (+24.72%)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Stanley Druckenmiller 413,000 sh (unchged)
Murray Stahl 24,000 sh (unchged)
John Burbank Sold Out
Joel Greenblatt Sold Out
George Soros 144,500 sh (-3.67%)
RS Investment Management 536,011 sh (-13.83%)
Pioneer Investments 515,939 sh (-24.84%)
Chuck Royce 307,800 sh (-27.71%)
Steven Cohen 30,257 sh (-49.99%)
Jim Simons 125,920 sh (-61.21%)
» More
Q1 2014

CBST Guru Trades in Q1 2014

Lee Ainslie 1,739,818 sh (New)
Jim Simons 189,091 sh (+50.17%)
Murray Stahl 24,000 sh (unchged)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Stanley Druckenmiller Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
RS Investment Management 504,845 sh (-5.81%)
Chuck Royce 219,900 sh (-28.56%)
Pioneer Investments 368,542 sh (-28.57%)
George Soros 50,000 sh (-65.4%)
Steven Cohen 3,082 sh (-89.81%)
» More
Q2 2014

CBST Guru Trades in Q2 2014

Ken Fisher 36,450 sh (New)
Vanguard Health Care Fund 1,467,542 sh (+10.91%)
Murray Stahl 24,000 sh (unchged)
Steven Cohen 394,200 sh (unchged)
George Soros Sold Out
Lee Ainslie Sold Out
Pioneer Investments 358,881 sh (-2.62%)
Chuck Royce 211,600 sh (-3.77%)
RS Investment Management 390,565 sh (-22.64%)
Jim Simons 47,420 sh (-74.92%)
» More
» Details

Insider Trades

Latest Guru Trades with CBST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Lee Ainslie 2014-06-30 Sold Out 1.8%$61.66 - $74.27 $ 70.934%0
George Soros 2014-06-30 Sold Out 0.04%$61.66 - $74.27 $ 70.934%0
Ken Fisher 2014-06-30 New Buy0.01%$61.66 - $74.27 $ 70.934%36450
Lee Ainslie 2014-03-31 New Buy1.8%$67.2 - $81.23 $ 70.93-5%1739818
Andreas Halvorsen 2014-03-31 Sold Out 0.24%$67.2 - $81.23 $ 70.93-5%0
George Soros 2014-03-31 Reduce -65.4%0.06%$67.2 - $81.23 $ 70.93-5%50000
John Burbank 2013-12-31 Sold Out 0.42%$61.59 - $70.76 $ 70.9310%0
Joel Greenblatt 2013-12-31 Sold Out 0.05%$61.59 - $70.76 $ 70.9310%0
Andreas Halvorsen 2013-12-31 Add 24.72%0.05%$61.59 - $70.76 $ 70.9310%741700
Michael Price 2013-09-30 Sold Out 1.2%$51.58 - $66.54 $ 70.9317%0
John Burbank 2013-09-30 New Buy0.42%$51.58 - $66.54 $ 70.9317%202451
Andreas Halvorsen 2013-09-30 New Buy0.21%$51.58 - $66.54 $ 70.9317%594704
George Soros 2013-06-30 New Buy0.09%$44.66 - $56.11 $ 70.9344%175000
John Hussman 2013-03-31 Sold Out 0.75%$40.78 - $48.06 $ 70.9360%0
Joel Greenblatt 2013-03-31 Reduce -72.24%0.18%$40.78 - $48.06 $ 70.9360%28134
Joel Greenblatt 2012-12-31 New Buy0.25%$39.17 - $48.63 $ 70.9365%101334
Joel Greenblatt 2012-09-30 Sold Out 0.12%$37.91 - $49.83 $ 70.9362%0
Joel Greenblatt 2012-06-30 Add 49.02%0.04%$38.38 - $44.07 $ 70.9374%41492
John Hussman 2012-03-31 Add 47.16%0.18%$38.77 - $44.72 $ 70.9384%674000
Joel Greenblatt 2012-03-31 Reduce -55.29%0.17%$38.77 - $44.72 $ 70.9384%27844
George Soros 2012-03-31 Sold Out 0.09%$38.77 - $44.72 $ 70.9384%0
Joel Greenblatt 2011-12-31 Reduce -53.85%0.42%$34.05 - $40.38 $ 70.9389%62273
John Hussman 2011-12-31 Add 798.04%0.26%$34.05 - $40.38 $ 70.9389%458000
George Soros 2011-12-31 Reduce -50%0.03%$34.05 - $40.38 $ 70.9389%50000
Michael Price 2011-09-30 Add 73.57%0.49%$29.59 - $36.93 $ 70.93108%182500
Joel Greenblatt 2011-09-30 Reduce -37.67%0.41%$29.59 - $36.93 $ 70.93108%134927
Vanguard Health Care Fund 2011-09-30 Add 49.25%0.08%$29.59 - $36.93 $ 70.93108%1323142
John Hussman 2011-09-30 New Buy0.03%$29.59 - $36.93 $ 70.93108%51000
George Soros 2011-09-30 Reduce -26.2%0.02%$29.59 - $36.93 $ 70.93108%100000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3733.20
CBST's P/E(ttm) is ranked higher than
81% of the 987 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 3733.20 )
CBST' s 10-Year P/E(ttm) Range
Min: 7.41   Max: 3802.11
Current: 3733.2

7.41
3802.11
P/B 3.59
CBST's P/B is ranked higher than
74% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CBST: 3.59 )
CBST' s 10-Year P/B Range
Min: 1.85   Max: 81.28
Current: 3.59

1.85
81.28
P/S 4.92
CBST's P/S is ranked higher than
84% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.61 vs. CBST: 4.92 )
CBST' s 10-Year P/S Range
Min: 1.98   Max: 150
Current: 4.92

1.98
150
PFCF 272.81
CBST's PFCF is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 272.81 )
CBST' s 10-Year PFCF Range
Min: 8.06   Max: 277.85
Current: 272.81

8.06
277.85
EV-to-EBIT 109.06
CBST's EV-to-EBIT is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 109.06 )
CBST' s 10-Year EV-to-EBIT Range
Min: -341   Max: 265.1
Current: 109.06

-341
265.1
Shiller P/E 54.06
CBST's Shiller P/E is ranked higher than
92% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 54.06 )
CBST' s 10-Year Shiller P/E Range
Min: 22.92   Max: 105.2
Current: 54.06

22.92
105.2
Current Ratio 0.51
CBST's Current Ratio is ranked higher than
50% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. CBST: 0.51 )
CBST' s 10-Year Current Ratio Range
Min: 0.47   Max: 14.48
Current: 0.51

0.47
14.48
Quick Ratio 0.44
CBST's Quick Ratio is ranked higher than
50% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. CBST: 0.44 )
CBST' s 10-Year Quick Ratio Range
Min: 0.4   Max: 14.48
Current: 0.44

0.4
14.48

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.22
CBST's Price/DCF (Projected) is ranked higher than
96% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 2.22 )
CBST' s 10-Year Price/DCF (Projected) Range
Min: 0.72   Max: 6.09
Current: 2.22

0.72
6.09
Price/Median PS Value 1.16
CBST's Price/Median PS Value is ranked higher than
81% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CBST: 1.16 )
CBST' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 49.32
Current: 1.16

0.52
49.32
Earnings Yield (Greenblatt) 0.90
CBST's Earnings Yield (Greenblatt) is ranked lower than
53% of the 312 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CBST: 0.90 )
CBST' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 23.3
Current: 0.9

0.4
23.3
Forward Rate of Return (Yacktman) -13.02
CBST's Forward Rate of Return (Yacktman) is ranked higher than
74% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: -9.72 vs. CBST: -13.02 )
CBST' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -39.1   Max: 102.6
Current: -13.02

-39.1
102.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU6.Germany
Cubist Pharmaceuticals, Inc. was incorporated as a Delaware corporation in 1992. It went public in 1996. The Company is engaged in the research, development & commercialization of novel therapies to treat unmet medical needs in acute care environment. It provides CUBICIN, a once-daily, bactericidal, intravenous antibiotic with activity against methicillin-resistant Staphylococcus aureus; and ENTEREG, an oral peripherally-acting mu opioid receptor antagonist to accelerate upper and lower gastrointestinal recovery. The company also co-promotes DIFICID for the treatment of clostridium difficile-associated diarrhea. In addition, its development products include Ceftolozane/tazobactam that is in Phase III clinical trials to treat complicated urinary tract infections and complicated intra-abdominal infections. Further, the company is developing ceftolozane/tazobactam for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Additionally, it develops Surotomycin, an oral lipopeptide, which is in Phase III clinical trials to treat CDAD; Bevenopran, an oral, peripherally-acting mu opioid receptor antagonist for the treatment of opioid-induced constipation in patients with chronic non-cancer pain; and CB-625 that is in Phase I clinical studies to treat acute pain and various inflammatory conditions. In addition, its pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain.
» More Articles for CBST

Headlines

Articles On GuruFocus.com
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Weekly CEO Sells Highlight: Saba Software Inc, Cubist Pharmaceuticals Inc, Polo Ralph Lauren Corp, P Apr 25 2010 
Cubist Pharmaceuticals Inc. (CBST) President and CEO Michael W Bonney sells 184,548 Shares Apr 23 2010 
Cubist Pharmaceuticals: A Drug Stock With Potential For Solid Gain Feb 15 2010 

More From Our Partners
Benzinga's Weekend M&A Chatter Oct 19 2014 - BENZINGA

More From Other Websites
Cubist Pharmaceuticals' Q3 Earnings Beat Expectations Oct 23 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 22 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits Oct 22 2014
Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's "Storm The Castle" Stock Oct 22 2014
Cubist Reports Third Quarter 2014 Financial Results Oct 21 2014
Cubist beats Street 3Q forecasts Oct 21 2014
Cubist beats Street 3Q forecasts Oct 21 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other... Oct 21 2014
Cubist Reports Third Quarter 2014 Financial Results Oct 21 2014
Q3 2014 Cubist Pharmaceuticals Inc Earnings Release - 4:00 pm ET Oct 21 2014
Bank Of America Q3 Small & Mid-Cap Biotech Preview Oct 20 2014
Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer Oct 20 2014
Cubist Pharmaceuticals Names Robert J. Perez Chief Executive Officer Oct 20 2014
Cubist to Announce Third Quarter 2014 Financial Results on Tuesday, October 21, 2014 Oct 14 2014
Cubist to Present New Data from Study of fidaxomicin in Children with Clostridium... Oct 08 2014
Actavis Expands Antibiotics Presence With Durata Buy Oct 06 2014
Cubist to Present New Data on Antibiotics Portfolio at IDWeek 2014 Sep 30 2014
White House calls for task force to tackle antibiotic-resistant bugs Sep 18 2014
Cubist Announces Continued Global Expansion with Opening of International Headquarters in Zurich Sep 18 2014
Cubist to Present New Data from Antibiotics Portfolio at 54th Interscience Conference on... Aug 26 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK